IRLAB Therapeutics AB
(FRA:6IRA)
€
0.12
+0.0032 (+2.72%)
Market Cap: 10.07 Mil
Enterprise Value: 7.94 Mil
PE Ratio: 0
PB Ratio: 2.81
GF Score: 41/100 Q2 2025 IRLAB Therapeutics AB Earnings Presentation Transcript
Aug 27, 2025 / 08:00AM GMT
Release Date Price:
€0.234595
(+0.64%)
Operator
Welcome to this live Q2 presentation by research company IRLAB, addressing Parkinson and other CNS diseases. Presenting today is CEO, Kristina Torfgard; Vice President, Research and Development, Nicholas Waters, and CFO, Viktor Siewertz.
After the presentation, there will be a Q&A with equity analysts and viewers can ask their questions in the live chat. I hereby welcome CEO, Kristina Torfgard. Please go ahead with your presentation.
Kristina Torfgard
IRLAB Therapeutics AB - Chief Executive Officer
Thank you very much, [Mattias]. So, this is our disclaimer and we are listed on Nasdaq Stockholm main
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot